Patrik Strömberg Joins AAX Biotech Board, Bringing Extensive Pharma Experience

New member of the board for a biotech startup Patrik Strömberg of AAX Biotech has over twenty years of expertise in the pharmaceutical sector with a strong foundation in business growth, innovation management, and research and development. Having held prominent roles at AstraZeneca and Biovitrum/Sobi, among other pharmaceutical businesses, he has a wealth of knowledge. Since 2021, Strömberg has served as AnaCardio's CEO. He graduated from Stockholm University with an MBA and Karolinska Institutet with a PhD in biochemistry. Experts from Stockholm, Sweden's Karolinska Institutet created AAX Biotech.